Sigma Life Science has released the first in its collection of breast cancer-specific knock-out and knock-in cell lines for drug discovery and research.
Part of Sigma's Compozr Oncology Disease Model portfolio, these modified epithelial cell lines are expected to provide researchers with a characterised and known genetic background for basic research and pathway analysis.
They are supplied with isogenic parental cell lines to allow high-throughput, cell-based screening for drug discovery, target validation and mechanistic studies.
